Skip to Content

Sanvar Approval Status

Sanvar (vapreotide acetate) is a somatostatin analogue in development for the treatment of acute esophageal variceal bleeding (EVB).

Development Status and FDA Approval Process for Sanvar

DateArticle
Nov  6, 2008Debiopharm Submits Response to the FDA for Sanvar (Debio 8609) for Esophageal Variceal Bleeding
Jan  5, 2005H3 Pharma Receives Approvable Letter from FDA for Sanvar for Esophageal Variceal Bleeding
Mar  2, 2004H3 Pharma Inc. Submits New Drug Application To FDA for Sanvar IR

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide